Hepatitis C affects the liver in humans and it is caused by Hepatitis C Virus (HCV) which has an RNA structure (World Gastroenterology Organisation, 2013). According to the National Institute of Health (2010) in the United Kingdom, individuals acquire the infection through percutaneous exposure to infected blood. Additionally, 30 percent of the infected people develop acute Hepatitis C (Goldberg & Anderson, 2004). In the event that the virus is not cleared after treatment, about 80 percent of individuals develop the chronic form of the infection (National Institute for Health and Clinical Excellence, 2010). The department of Public Health England (2013) estimates that 215,000 patients are infected with the chronic form of the disease in the United Kingdom; the prevalence of the infection in England is about 40 cases per 10,000 populations. There are variations in the ethnicity of the individuals that are infected as most infections have been reported among people of South Asian origin (Public Health England, 2013). The prevention and control strategies in England focus on the populations at-risk of the infection and majorly target injecting drug users (Public Health England, 2013). Although these strategies have been effective in the past, the cases of HVC in England are still high (Health Protection Agency, 2012). According to the Health Protection Agency (2012), the disease is projected to cause 15,840 cases of liver cancer and cirrhosis by 2020 if majority of the cases continue to be untreated. The trends between 1997 and 2008 showed that the number of patients with cancer and other HCV related complications had been increasing over the years as shown in the figure (2) below; Figure (2) showing the number of patients hospitalized with liver cancer and other liver diseases associated with HCV infection between 1997 and 2007 (adapted from Health Protection Agency, 2009) The increase in number of cases of liver cancer and cirrhosis may elicit a huge burden on the health care system in the United Kingdom and may result in many deaths (Health Protection Agency, 2012). The England Action Plan for Hepatitis C (2004) indicates that the testing should focus on the people who are most susceptible to the infection especially intravenous drug users. Based on a report by the Public Health England (2013), the prevalence of the disease among injecting drug users ranges from 17 to 82 percent and it varies across different regions in the United Kingdom. Current prevention and control strategy in England and its effectiveness The Public Heath England (2013), reports that England has continued to upgrade the prevention and control mechanisms that regard to hepatitis C infections. Since the control and prevention of HCV in the United Kingdom target on the susceptible populations, England has invested in effective community drug treatments that are accessible to the most-at-risk populations (Public Health England, 2013). There was an escalation of 114,855 individuals that received medication among those that abused injectable drugs between 2010 and 2011. The Drug Action Teams in the country have also developed other mechanisms for hepatitis C prevention that focus on drug misuse and sexual health (Health Protection Agency, 2012). O